loader
Please Wait
Applying Filters...

Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 17050 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Dipharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Temad- We think of world-class quality.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Dipharma (1)

    filter

    01 CILOSTAZOL (1)

    filter

    01 Italy (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    DIPHARMA FRANCIS SRL

    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    CILOSTAZOL

    PDF Supplier PDF
    URL Supplier Web Content
    17050
    Active
    2003-12-22
    Complete
    2019-02-27
    2019-02-25
    II
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for Drug Master Files (DMF) for 17050 of Dipharma Francis Srl

    Looking for Drug Master Files (DMF) for 17050 of Dipharma Francis Srl 1

    20

    Dipharma Francis Srl, based in Italy, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

    One of their notable products is CILOSTAZOL, with a corresponding US DMF Number 17050.

    Remarkably, this DMF maintains an Active status since its submission on December 22, 2003, highlighting commitment to regulatory compliance.

    Their GDUFA DMF Review was successfully complete, with a review date of February 27, 2019, and payment made on February 25, 2019, indicating their dedication to facilitating drug approvals, Categorized as Type II

    Post Enquiry
    POST ENQUIRY